The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| IMUX | -39.1% | -95.8% | -46.92% | -97% |
| S&P | +12.65% | +91.73% | +13.89% | +132% |
Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis, and psoriasis. The firm’s products include IMU-838, IMU-935, and IMU-856. The company is headquartered in New York, NY.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.04M | -38.7% |
| Market Cap | $66.83M | -33.2% |
| Market Cap / Employee | $0.73M | 0.0% |
| Employees | 91 | 18.2% |
| Net Income | -$26.82M | -25.4% |
| EBITDA | -$27.04M | -18.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $55.31M | -30.6% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.21M | -14.9% |
| Short Term Debt | $0.77M | 8.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -137.69% | -28.9% |
| Return On Invested Capital | -211.93% | -95.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$24.65M | -43.2% |
| Operating Free Cash Flow | -$24.61M | -44.5% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.34 | 2.19 | 5.33 | -11.89 | -1094.03% |
| Price to Tangible Book Value | 2.34 | 2.19 | 5.33 | -11.89 | -1094.10% |
| Enterprise Value to EBITDA | -4.24 | -2.17 | -3.63 | -1.40 | -5.25% |
| Return on Equity | -216.2% | -424.4% | -246.3% | -208.9% | 45.63% |
| Total Debt | $0.90M | $1.00M | $0.98M | $0.98M | 2.51% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
